Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Cancer

Finding Markers For Liver Cancer

Hepatocellular carcinoma (HCC) is a common and often fatal liver cancer – but early detection could offer better outcomes for patients. Luckily, detection rates could be improved thanks to a recent study that showed a liver tsRNA – named tRF-Gln-TTG-006 – may have promise as an early blood biomarker for liver cancer. Alongside the knowledge that the tsRNA could indicate HCC, the team also found that it may play a biological role in the development of the disease (1).

Because the serum tsRNA signature in HCC has yet to be elucidated, the study adapted high-throughput sequencing capable of identifying hundreds of undiscovered tsRNAs. These new tsRNAs were then screened and vetted through a two-stage validation process, resulting in the discovery of tRF-Gln-TTG-006, which may identify HCC patients with significantly better accuracy than the commonly used α-fetoprotein biomarker.

The researchers also found that non-coding RNAs may play a large part in cell communication, suggesting a complex relationship between tumor, microenvironment, and immune cells.

Numerous assays demonstrated that tRF-Gln-TTG-006 has a repressive effect on HCC cells, highlighting its potential role as both a predictive biomarker and a functional regulator of HCC. The authors speculate that tsRNAs may harm HCC, causing the cancer cells to secure their survival by excreting tsRNAs to the serum. This may explain the significantly elevated levels of tRF-Gln-TTG-006 in HCC serum.

Though the study offers hope for improved outcomes, randomized clinical trials are needed to evaluate tRF-Gln-TTG-006’s potential as a diagnostic and prognostic tool for HCC.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. S Zhan et al., Front. Med, 16, 216 (2022). PMID: 35416630.
About the Author
George Lee

Associate Editor, The Pathologist

Like most people, I didn’t know exactly what I wanted to do after university. But one thing was certain – writing would play a central role. Not one to walk the path most traveled, I decided to spend my next few years freelancing to hone my skills as a writer and further cement my love for language. Reaching people through writing is important to me and I look forward to connecting with thousands of people through Texere’s passionate audience.

Related Solutions
Biomarker Optimization on LabSat® Research

| Contributed by Epredia

One Week to One Day

| Contributed by Epredia

Disease Area Cancer
See how droplets are guiding precision medicine

| Contributed by Bio Rad

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register